Skip Navigation

JNCI Journal of the National Cancer Institute 1999 91(5):404-406; doi:10.1093/jnci/91.5.404
© 1999 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Reynolds, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reynolds, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 91, No. 5, 404-406, March 3, 1999
© 1999 Oxford University Press

NEWS

Treating the Most Intractable Cancers Progresses Slowly

Tom Reynolds

Among the most dreaded diagnoses in medicine are cancers that have defied decades of scientific effort to find effective therapies. Nearly all cancer patients are offered some sort of treatment, and for the vast majority, standard therapies exist. But for the most intractable diseases — including certain cancers of the brain, kidney, liver, pancreas, and skin — current treatments offer little survival benefit and virtually no chance of cure.

As always, there is hope on the horizon — vaccines and immunotherapies, improved surgical techniques, targeted radiation beams and implants, and novel chemotherapy agents and delivery systems.

And the situation is improved from a decade ago when there were a half-dozen or so cancers with no standard treatment at all, said Scott Saxman, M.D., of the National Cancer . . . [Full Text of this Article]

Role for Sex Hormones

No Placebo Arm


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?